デフォルト表紙
市場調査レポート
商品コード
1607749

IPS細胞由来オルガノイドの世界市場:タイプ・用途・エンドユーザー・地域別の予測 (~2032年)

Global IPS Cell Derived Organoids Market Research Report Information by Type, by Application, by End User, and by Region Forecast till 2032


出版日
ページ情報
英文 101 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.81円
IPS細胞由来オルガノイドの世界市場:タイプ・用途・エンドユーザー・地域別の予測 (~2032年)
出版日: 2024年11月21日
発行: Market Research Future
ページ情報: 英文 101 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のIPS細胞由来オルガノイドの市場規模は、2023年の4億4,000万米ドル、2024年の5億1,000万米ドルから、予測期間中は17.8%のCAGRで推移し、2032年には18億9,000万米ドルの規模に成長すると予測されています。

IPS細胞由来オルガノイドの市場は、生物医学研究と医薬品開発における画期的な進歩を象徴しています。人工多能性幹細胞(iPS細胞)から作製されるこれらの小型3次元組織モデルは、ヒトの生理学、疾病メカニズム、薬効を研究するための前例のない機会を提供します。オルガノイドは、疾患モデル、創薬、個別化医療、再生療法など、さまざまな用途に用いられています。iPS細胞由来オルガノイド市場は、技術の進歩、個別化医療に対する需要の増加、創薬や再生医療における用途の拡大に牽引され、大幅な成長が見込まれています。一方で、この革新的技術の可能性をフルに発揮するには、技術的、規制的、倫理的課題を克服することが極めて重要です。

地域別インサイト

北米のIPS細胞由来オルガノイド市場は、強固な研究インフラ、ライフサイエンスへの多額の投資、盛んなバイオテクノロジー産業を有しています。同地域には幹細胞研究の最前線にある一流大学や研究センターがいくつかあり、また、市場はiPS細胞由来オルガノイドの開発と応用を推進するために官民双方から多額の投資を受けています。北米では医療制度が確立しているため、先進医療技術の導入が容易です。洗練された研究施設と熟練した専門家の存在も市場の成長をさらに後押ししています。同地域の技術導入への取り組みは、オルガノイドベースのプラットフォームの開発と応用を促進しています。支持的な規制の枠組みもオルガノイド研究開発への投資を後押ししています。

欧州はヘルスケアへの焦点と、強力な科学コミュニティが市場を牽引しているためことから、IPS細胞由来オルガノイド市場で第2位のシェアを占めています。ドイツのIPS細胞由来オルガノイドプロバイダーが最大の市場シェアを占め、フランスのIPS細胞由来オルガノイドプロバイダーは同地域でもっとも急成長していると予測されています。

アジア太平洋のIPS細胞由来オルガノイド市場は、生物医学研究への投資の増加、医療支出の増加、慢性疾患の有病率の上昇によるIPS細胞由来オルガノイドの研究開発の促進などから、2023年から2032年にかけてもっとも急成長すると予測されています。

当レポートでは、世界のIPS細胞由来オルガノイドの市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

  • 促進要因
    • 個別化医薬品の採用拡大
    • 慢性疾患の拡大
    • 幹細胞研究の進歩
    • 促進要因の影響分析
  • 抑制要因
    • オルガノイドの開発と維持にかかる高コスト性
    • 規制上のハードルと標準化
    • 抑制要因の影響分析
  • 機会
    • より複雑で機能的なオルガノイドの開発
    • 創薬と毒物学における応用の拡大
  • COVID-19の影響分析

第5章 市場要因分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析

第6章 世界のIPS細胞由来オルガノイド市場:タイプ別

  • 概要
  • 心臓
  • 肝臓
  • 腎臓
  • その他

第7章 世界のIPS細胞由来オルガノイド市場:用途別

  • 概要
  • 医薬品の発見・開発
  • 疾患モデリング
  • 再生医療

第8章 世界のIPS細胞由来オルガノイド市場:エンドユーザー別

  • 概要
  • 製薬・バイオテクノロジー企業
  • 学術研究機関
  • CRO

第9章 世界のIPS細胞由来オルガノイド市場:地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第10章 競合情勢

  • 主要な成長戦略
  • 競合ダッシュボード

第11章 企業プロファイル

  • ACROBIOSYSTEMS
  • MILTENYI BIOTEC
  • THERMOFISHER SCIENTIFIC
  • STEMCELL TECHNOLOGIES
  • BIO-TECHNE
  • MERCK KGAA
  • MOLECULAR DEVICES, LLC
  • CORNING INCORPORATED
  • PROMEGA CORPORATION
  • CREATIVE BIOARRAY
図表

LIST OF TABLES

  • TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
  • TABLE 2 GLOBAL: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 3 GLOBAL: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 4 GLOBAL: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 5 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 6 NORTH AMERICA: IPS CELL-DERIVED ORGANOIDS MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 7 NORTH AMERICA: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 8 NORTH AMERICA: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 9 NORTH AMERICA: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 10 USA: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 11 USA: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 12 USA: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 13 CANADA: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 14 CANADA: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 15 CANADA: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 16 EUROPE: IPS CELL-DERIVED ORGANOIDS MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 17 EUROPE: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 18 EUROPE: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 19 EUROPE: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 20 GERMANY: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 21 GERMANY: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 22 GERMANY: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 23 UK: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 24 UK: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 25 UK: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 26 FRANCE: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 27 FRANCE: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 28 FRANCE: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 29 ITALY: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 30 ITALY: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 31 ITALY: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 32 SPAIN: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 33 SPAIN: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 34 SPAIN: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 35 REST OF EUROPE: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 36 REST OF EUROPE: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 37 REST OF EUROPE: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: IPS CELL-DERIVED ORGANOIDS MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 40 ASIA PACIFIC: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 41 ASIA PACIFIC: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 42 CHINA: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 43 CHINA: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 44 CHINA: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 45 INDIA: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 46 INDIA: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 47 INDIA: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 48 JAPAN: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 49 JAPAN: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 50 JAPAN: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 51 SOUTH KOREA: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 52 SOUTH KOREA: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 53 SOUTH KOREA: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 54 AUSTRALIA: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 55 AUSTRALIA: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 56 AUSTRALIA: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 57 REST OF APAC: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 58 REST OF APAC: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 59 REST OF APAC: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 60 REST OF THE WORLD: IPS CELL-DERIVED ORGANOIDS MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 61 REST OF WORLD: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 62 REST OF WORLD: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 63 REST OF WORLD: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 64 MIDDLE EAST & AFRICA: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 65 MIDDLE EAST & AFRICA: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 66 MIDDLE EAST & AFRICA: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 67 SOUTH AMERICA: IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 68 SOUTH AMERICA: IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 69 SOUTH AMERICA: IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 70 ACROBIOSYSTEMS: PRODUCTS OFFERED
  • TABLE 71 ACROBIOSYSTEMS: KEY DEVELOPMENTS
  • TABLE 72 MILTENYI BIOTEC: PRODUCTS OFFERED
  • TABLE 73 THERMO FISHER SCIENTIFIC INC: PRODUCTS OFFERED
  • TABLE 74 STEMCELL TECHNOLOGIES: PRODUCTS OFFERED
  • TABLE 75 BIO-TECHNE CORP: PRODUCTS OFFERED
  • TABLE 76 MERCK KGAA: PRODUCTS OFFERED
  • TABLE 77 MOLECULAR DEVICES.: PRODUCTS OFFERED
  • TABLE 78 CORNING INCORPORATED: PRODUCTS OFFERED
  • TABLE 79 PROMEGA CORPORATION.: PRODUCTS OFFERED
  • TABLE 80 CREATIVE BIOARRAY: PRODUCTS OFFERED

LIST OF FIGURES

  • FIGURE 1 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET: STRUCTURE
  • FIGURE 2 MARKET DYNAMICS: GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET
  • FIGURE 3 DRIVER IMPACT ANALYSIS: GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET
  • FIGURE 4 RESTRAINT IMPACT ANALYSIS: GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET
  • FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET
  • FIGURE 6 SUPPLY CHAIN ANALYSIS: GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET
  • FIGURE 7 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2023 (% SHARE)
  • FIGURE 8 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE, 2019-2032 (USD MILLION)
  • FIGURE 9 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION, 2023 (% SHARE)
  • FIGURE 10 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY PRICING, 2019-2032 (USD MILLION)
  • FIGURE 11 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER, 2023 (% SHARE)
  • FIGURE 12 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY AGE CATEGORY, 2019-2032 (USD MILLION)
  • FIGURE 13 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY REGION, 2023 (% SHARE)
  • FIGURE 14 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY REGION, 2019-2032 (USD MILLION)
  • FIGURE 15 NORTH AMERICA: IPS CELL-DERIVED ORGANOIDS MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 16 EUROPE: IPS CELL-DERIVED ORGANOIDS MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 17 ASIA PACIFIC: IPS CELL-DERIVED ORGANOIDS MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 18 MIDDLE EAST & AFRICA: IPS CELL-DERIVED ORGANOIDS MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 19 COMPETITOR DASHBOARD: GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET
  • FIGURE 20 ACROBIOSYSTEMS: SWOT ANALYSIS
  • FIGURE 21 MILTENYI BIOTEC: SWOT ANALYSIS
  • FIGURE 22 THERMO FISHER SCIENTIFIC INC: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 23 THERMO FISHER SCIENTIFIC INC: SWOT ANALYSIS
  • FIGURE 24 STEMCELL TECHNOLOGIES: SWOT ANALYSIS
  • FIGURE 25 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 26 MERCK KGAA: SWOT ANALYSIS
  • FIGURE 27 CORNING INCORPORATED: FINANCIAL OVERVIEW SNAPSHOT
目次
Product Code: MRFR/HC/26930-CR

Global IPS Cell Derived Organoids Market Research Report Information by Type (Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids, and Others), by Application (Drug Discovery and Development, Disease Modelling, and Regenerative Medicine), by End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Contract Research Organization), and by Region (North America, Europe, Asia-Pacific, and Rest of the World Forecast till 2032

An Overview of the Market

IPS Cell Derived Organoids Market size was valued at USD 0.44 billion in 2023. The IPS Cell Derived Organoids Market industry is projected to grow from USD 0.51 billion in 2024 to USD 1.89 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 17.8% during the forecast period (2024 - 2032).

IPS cell-derived organoids market represent a revolutionary advancement in biomedical research and drug development. These miniature, three-dimensional tissue models, generated from induced pluripotent stem cells (iPSCs), offer unprecedented opportunities for studying human physiology, disease mechanisms, and drug efficacy. Organoids are used in various applications, including disease modelling, drug discovery, personalized medicine, and regenerative therapies. The iPS cell-derived organoids market is poised for substantial growth, driven by technological advancements, increasing demand for personalized medicine, and expanding applications in drug discovery and regenerative medicine. However, overcoming technical, regulatory, and ethical challenges will be crucial for realizing the full potential of this transformative technology.

Market segmentation insights

The IPS Cell Derived Organoids Market segmentation, based on type, includes Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids, and Others.

The IPS Cell Derived Organoids Market segmentation, based on application, includes drug discovery and development, disease modelling, and regenerative medicine.

Regional Insights

The IPS Cell Derived Organoids market in America boasts a robust research infrastructure, substantial investments in life sciences, and a thriving biotechnology industry. North America is home to several top-tier universities and research centers that are at the forefront of stem cell research. This region has seen substantial investments from both public and private sectors aimed at advancing the development and application of iPS cell-derived organoids. The well-established healthcare systems in North America facilitate the adoption of advanced medical technologies. The presence of sophisticated laboratory facilities and skilled professionals further supports market growth. The region's inclination towards technological adoption has fostered the development and application of organoid-based platforms. Supportive regulatory frameworks encourage investments in organoid research and development.

Europe IPS Cell Derived Organoids market accounted for the second-largest market share due to region's emphasis on healthcare, coupled with a strong scientific community, drives the market. Furthermore, the Germany IPS Cell Derived Organoids provider attributed to hold the largest market share, and the France IPS Cell Derived Organoids providers is projected be the fastest growing market in the Europe region.

The Asia-Pacific IPS Cell Derived Organoids market is expected to be the fastest growing from 2023 to 2032 due to increasing investments in biomedical research, growing healthcare expenditure, and a rising prevalence of chronic diseases can support IPS Cell Derived Organoids development.

Prominent Participants

Key Companies in the IPS Cell Derived Organoids market includes ACROBiosystems (US), Miltenyi Biotec (Germany), ThermoFisher Scientific (US), STEMCELL Technologies (Canada), Bio-Techne (US), Merck KGaA (Germany), Molecular Devices, LLC (US), Corning Incorporated (US), Promega Corporation (US), and Creative Bioarray (US).

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA FLOW
    • 3.2.1 DATA MINING PROCESS
  • 3.3 PURCHASED DATABASE:
  • 3.4 SECONDARY SOURCES:
    • 3.4.1 SECONDARY RESEARCH DATA FLOW:
  • 3.5 PRIMARY RESEARCH:
    • 3.5.1 PRIMARY RESEARCH DATA FLOW:
    • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
    • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
  • 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
    • 3.6.1 REVENUE ANALYSIS APPROACH
  • 3.7 DATA FORECASTING
    • 3.7.1 DATA FORECASTING TECHNIQUE
  • 3.8 DATA MODELING
    • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
    • 3.8.2 DATA MODELING:

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 GROWING ADOPTION OF PERSONALIZED DRUGS
    • 4.2.2 RISING PREVALENCE OF CHRONIC DISEASES
    • 4.2.3 ADVANCEMENTS IN STEM CELL RESEARCH
    • 4.2.4 DRIVER IMPACT ANALYSIS
  • 4.3 RESTRAINTS
    • 4.3.1 HIGH COST OF ORGANOID DEVELOPMENT AND MAINTENANCE
    • 4.3.2 REGULATORY HURDLES AND STANDARDIZATION
    • 4.3.3 RESTRAINT IMPACT ANALYSIS
  • 4.4 OPPORTUNITY
    • 4.4.1 DEVELOPMENT OF MORE COMPLEX AND FUNCTIONAL ORGANOIDS
    • 4.4.2 EXPANSION OF APPLICATIONS IN DRUG DISCOVERY AND TOXICOLOGY
  • 4.5 IMPACT ANALYSIS OF COVID -
    • 4.5.1 IMPACT ON OVERALL HEALTH INDUSTRY
    • 4.5.2 IMPACT ON GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET
    • 4.5.3 IMPACT ON SUPPLY CHAIN OF IPS CELL-DERIVED ORGANOIDS
    • 4.5.4 IMPACT ON MARKET DEMAND OF IPS CELL-DERIVED ORGANOIDS
    • 4.5.5 IMPACT ON PRICING OF IPS CELL-DERIVED ORGANOIDS

5 MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S FIVE FORCES MODEL
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 BARGAINING POWER OF SUPPLIERS
    • 5.1.3 BARGAINING POWER OF BUYERS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF RIVALRY
  • 5.2 SUPPLY CHAIN ANALYSIS
    • 5.2.1 RAW MATERIAL
    • 5.2.2 PRODUCTION PROCESS
    • 5.2.3 DISTRIBUTION
    • 5.2.4 END USER

6 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY TYPE

  • 6.1 OVERVIEW
  • 6.2 BRAIN
  • 6.3 HEART
  • 6.4 LUNG
  • 6.5 LIVER
  • 6.6 KIDNEY
  • 6.7 OTHERS

7 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY APPLICATION

  • 7.1 OVERVIEW
  • 7.2 DRUG DISCOVERY AND DEVELOPMENT
  • 7.3 DISEASE MODELLING
  • 7.4 REGENERATIVE MEDICINE

8 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY END USER

  • 8.1 OVERVIEW
  • 8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 8.3 ACADEMIC AND RESEARCH INSTITUTES
  • 8.4 CONTRACT RESEARCH ORGANIZATION

9 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY REGION

  • 9.1 OVERVIEW
    • 9.1.1 GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET, BY REGION, 2020-2032
  • 9.2 NORTH AMERICA
    • 9.2.1 NORTH AMERICA: IPS CELL-DERIVED ORGANOIDS MARKET, BY COUNTRY, 2020-2032
  • 9.3 EUROPE
    • 9.3.1 EUROPE: IPS CELL-DERIVED ORGANOIDS MARKET, BY COUNTRY, 2020-2032
  • 9.4 ASIA PACIFIC
    • 9.4.1 ASIA PACIFIC: IPS CELL-DERIVED ORGANOIDS MARKET, BY COUNTRY, 2020-2032
  • 9.5 REST OF THE WORLD
    • 9.5.1 REST OF THE WORLD: IPS CELL-DERIVED ORGANOIDS MARKET, BY COUNTRY, 2020-2032

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 MAJOR GROWTH STRATEGY IN THE GLOBAL IPS CELL-DERIVED ORGANOIDS MARKET
  • 10.3 COMPETITOR DASHBOARD

11 COMPANY PROFILES

  • 11.1 ACROBIOSYSTEMS
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 FINANCIAL OVERVIEW
    • 11.1.3 PRODUCTS OFFERED
    • 11.1.4 KEY DEVELOPMENTS
    • 11.1.5 SWOT ANALYSIS
    • 11.1.6 KEY STRATEGIES
  • 11.2 MILTENYI BIOTEC
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 FINANCIAL OVERVIEW
    • 11.2.3 PRODUCTS OFFERED
    • 11.2.4 KEY DEVELOPMENTS
    • 11.2.5 SWOT ANALYSIS
    • 11.2.6 KEY STRATEGIES
  • 11.3 THERMOFISHER SCIENTIFIC
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 FINANCIAL OVERVIEW
    • 11.3.3 PRODUCTS OFFERED
    • 11.3.4 KEY DEVELOPMENTS
    • 11.3.5 SWOT ANALYSIS
    • 11.3.6 KEY STRATEGIES
  • 11.4 STEMCELL TECHNOLOGIES
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 FINANCIAL OVERVIEW
    • 11.4.3 PRODUCTS OFFERED
    • 11.4.4 KEY DEVELOPMENTS
    • 11.4.5 SWOT ANALYSIS
    • 11.4.6 KEY STRATEGIES
  • 11.5 BIO-TECHNE
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 FINANCIAL OVERVIEW
    • 11.5.3 PRODUCTS OFFERED
    • 11.5.4 KEY DEVELOPMENTS
    • 11.5.5 KEY STRATEGIES
  • 11.6 MERCK KGAA
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 FINANCIAL OVERVIEW
    • 11.6.3 PRODUCTS OFFERED
    • 11.6.4 KEY DEVELOPMENTS
    • 11.6.5 SWOT ANALYSIS
    • 11.6.6 KEY STRATEGIES
  • 11.7 MOLECULAR DEVICES, LLC
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 FINANCIAL OVERVIEW
    • 11.7.3 PRODUCTS OFFERED
    • 11.7.4 KEY DEVELOPMENTS
    • 11.7.5 KEY STRATEGIES
  • 11.8 CORNING INCORPORATED
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 FINANCIAL OVERVIEW
    • 11.8.3 PRODUCTS OFFERED
    • 11.8.4 KEY DEVELOPMENTS
    • 11.8.5 KEY STRATEGIES
  • 11.9 PROMEGA CORPORATION
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 FINANCIAL OVERVIEW
    • 11.9.3 PRODUCTS OFFERED
    • 11.9.4 KEY DEVELOPMENTS
    • 11.9.5 KEY STRATEGIES
  • 11.10 CREATIVE BIOARRAY
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 FINANCIAL OVERVIEW
    • 11.10.3 PRODUCTS OFFERED
    • 11.10.4 KEY DEVELOPMENTS
    • 11.10.5 KEY STRATEGIES